NCT03958877 / 2018-003008-38: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis |
|
|
| Recruiting | 3 | 142 | Europe, US, RoW | BIIB017 (peginterferon beta-1a), PLEGRIDY, Interferon beta type 1a, Avonex | Biogen | Multiple Sclerosis, Relapsing-Remitting | 07/24 | 05/27 | | |
